|
06/03/20
|
Vaxart to Present at the Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , June 03, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“ Vaxart” or the “Company”) (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced today announced that
|
|
05/20/20
|
Vaxart Announces Selection of its Oral COVID-19 Vaccine Lead Candidate
KindredBio Selected as Second Contract Manufacturing Organization GMP Production for Phase 1 Study Initiated SOUTH SAN FRANCISCO, Calif. , May 20, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“ Vaxart” or the “Company”) (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant
|
|
05/12/20
|
Vaxart Announces First Quarter 2020 Financial Results and Provides Corporate Update
Lead Vaccine Candidates for COVID-19 are Highly Immunogenic in Preclinical Testing COVID-19 Phase 1 Clinical Study Planned for 2H20 SOUTH SAN FRANCISCO, Calif. , May 12, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral
|
|
04/30/20
|
Vaxart Announces Additional Positive Pre-Clinical Data for its Oral COVID-19 Vaccine Program
Robust Boosting of Immune Responses Observed after Second Dose SOUTH SAN FRANCISCO, Calif. , April 30, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that
|
|
04/28/20
|
Vaxart Announces Corporate Update for First Quarter 2020
Preparations for the Manufacturing of GMP Vaccine at Emergent BioSolutions Ongoing Vaxart is Participating in Maxim’s Infectious Disease Virtual Conference on May 5, 2020 SOUTH SAN FRANCISCO, Calif. , April 28, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company
|
|
04/21/20
|
Vaxart Announces Positive Pre-Clinical Data for its Oral COVID-19 Vaccine Program
Lead Vaccine Candidates Generate Anti-SARS CoV-2 Antibodies in All Tested Animals after First Dose SOUTH SAN FRANCISCO, Calif. , April 21, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than
|
|
03/31/20
|
Vaxart Provides Update on its Oral COVID-19 Vaccine Program
Five COVID-19 Vaccine Candidates in Preclinical Testing Development Services to Enable Manufacture of cGMP Vaccine at Emergent BioSolutions have Started SOUTH SAN FRANCISCO, Calif. , March 31, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant
|
|
03/19/20
|
Vaxart Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Company Focuses on COVID-19 Program, the First Oral Coronavirus Vaccine Raised total of $19.8 Million from a Registered Direct Offering and Warrant Exercises during Q1 2020 SOUTH SAN FRANCISCO, Calif. , March 19, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company
|
|
03/18/20
|
VAXART ANNOUNCES IT ENTERED INTO AN AGREEMENT WITH EMERGENT BIOSOLUTIONS FOR THE DEVELOPMENT AND MANUFACTURING OF ORAL CORONAVIRUS (COVID-19) VACCINE CANDIDATE
Oral Vaccines based on Proprietary VAAST™ Platform Offer Potential Key Advantages in Global Quest to Develop Coronavirus Vaccine SOUTH SAN FRANCISCO, Calif. , March 18, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines
|
|
02/27/20
|
Vaxart Announces $10.0 Million Registered Direct Offering Priced At-the-Market
SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into definitive agreements with several
|
